文献速递造血干细胞移植与细胞治疗白血病

γδ T细胞在同种异体造血干细胞移植治疗白血病中的潜在作用

The potential role of γδ T cells after allogeneic HCT for leukemia.
PubMed 文献 · Blood · 2018-01-22

同种异体造血干细胞移植(HCT)可恢复功能性造血与免疫并发挥移植物抗白血病(GVL)效应,但伴随GVHD和感染风险。表达αβ T细胞受体的同种反应性T淋巴细胞引起GVHD,而表达γδ T细胞受体的淋巴细胞无同种反应性、不诱导GVHD,却具有强效抗白血病和抗感染活性。因此γδ T细胞在异基因HCT中日益受关注,通过药物或抗体在体内激活移植后γδ T细胞或其亚群,或体外扩增操作患者或供者来源γδ T细胞及其亚群并过继转移的策略正在开发。基于其无失调的同种反应性,此类方法有望在无GVHD的情况下诱导强效GVL效应。建立大规模临床方法富集、分离、扩增和操作γδ T细胞将促进未来临床研究以充分利用这些有益的非同种反应性淋巴细胞的功能。

要点

  • αβ T细胞介导GVHD,γδ T细胞无同种反应性、不诱导GVHD。
  • γδ T细胞具有强效抗白血病和抗感染活性。
  • 策略包括体内激活或体外扩增γδ T细胞及亚群后过继转移。

核心结论

  • 基于γδ T细胞无失调的同种反应性,相关策略有望在无GVHD的情况下诱导强效GVL效应。
  • 建立大规模临床方法富集、分离、扩增和操作γδ T细胞将促进未来临床研究以充分利用这些有益的非同种反应性淋巴细胞的功能。

研究设计与样本

  • 本文为综述,讨论γδ T细胞在同种异体HCT治疗白血病中的潜在作用及临床策略。

主要发现

  • 表达αβ T细胞受体的同种反应性T淋巴细胞引起GVHD。
  • 表达γδ T细胞受体的淋巴细胞无同种反应性、不诱导GVHD,但可表现出强效抗白血病和抗感染活性。
  • 策略包括通过某些药物或抗体在HCT后体内激活γδ T细胞或其亚群。
  • 策略包括体外扩增和操作患者来源或供者来源的γδ T细胞及其亚群,并过继转移体外激活的淋巴细胞。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Allogeneic hematopoetic stem cell transplantation (HCT) offers an option for patients with hematologic malignancies, in whom conventional standard therapies failed or are not effective enough to cure the disease. Successful HCT can restore functional hematopoiesis and immune function, and the new donor-derived immune system can exert a graft-versus-leukemia (GVL) effect. However, allogenic HCT can also be associated with serious risks for transplantation-related morbidities or mortalities such as graft-versus-host disease (GVHD) or life-threatening infectious complications. GVHD is caused by alloreactive T lymphocytes, which express the αβ T-cell receptor, whereas lymphocytes expressing the γδ T-cell receptor are not alloreactive and do not induce GVHD but can exhibit potent antileukemia and anti-infectious activities. Therefore, γδ T cells are becoming increasingly interesting in allogeneic HCT, and clinical strategies to exploit the full function of these lymphocytes have been and are being developed. Such strategies comprise the in vivo activation of γδ T cells or subsets after HCT by certain drugs or antibodies or the ex vivo expansion and manipulation of either patient-derived or donor-derived γδ T cells and their subsets and the adoptive transfer of the ex vivo-activated lymphocytes. On the basis of the absence of dysregulated alloreactivity, such approaches could induce potent GVL effects in the absence of GVHD. The introduction of large-scale clinical methods to enrich, isolate, expand, and manipulate γδ T cells will facilitate future clinical studies that aim to exploit the full function of these beneficial nonalloreactive lymphocytes.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Handgretinger R, Schilbach K. The potential role of γδ T cells after allogeneic HCT for leukemia. Blood. 2018. PMID: 29358176. doi:10.1182/blood-2017-08-752162

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。